<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004889</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067565</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-9909016</secondary_id>
    <secondary_id>NCI-G00-1709</secondary_id>
    <nct_id>NCT00004889</nct_id>
  </id_info>
  <brief_title>Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia</brief_title>
  <official_title>Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
      tumor-killing substances to them without harming normal cells.

      PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have
      Waldenstrom's macroglobulinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the objective response, time to treatment failure, and toxicity in
      patients with Waldenstrom's macroglobulinemia treated with rituximab. II. Correlate
      expression and changes in expression of CD20 on patient plasma cells and B-cells with
      clinical responses.

      OUTLINE: This is a multicenter study. Patients receive rituximab IV weekly for 4 weeks.
      Treatment may be repeated 2 months later in patients with stable disease, partial response,
      or complete response. Patients are followed every 6 months for 2 years.

      PROJECTED ACCRUAL: A total of 12-25 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response (delay in disease progression or timing of disease progression)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Define objective response (delay in disease progression or timing of disease progression), time to treatment failure, and toxicity for single agent Rituxan therapy in Waldenstrom's macroglobulinemia patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of CD20</measure>
    <time_frame>24 weeks</time_frame>
    <description>To correlate expression and changes in expression of CD20 on waldenstrom's macroglobulinemia patient plasma cells and B-cells with clinical responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituxan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.</description>
    <arm_group_label>Rituxan</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Waldenstrom's Macroglobulinemia requiring therapy who have received no more than 2
             prior courses of therapy; previously untreated patients with slowly progressive WM if
             the patient can reasonably be expected to not require chemotherapy or steroid therapy
             for 90 days

          -  CD20 positive tumor cells

          -  Presence of monoclonal paraprotein

          -  Minimum IgM level &gt; 2 times the upper limit of normal

          -  Adequate organ function: ANC&gt;1000/uL; PLT &gt; 25000/uL; serum creatinine &lt; 2.5; serum
             total bilirubin and SGOT &lt; 2.5 times the upper limit of normal

          -  18 years and older

          -  Life expectancy of 6 months or greater

          -  ECOG performance status of 0-2

          -  Men and women of reproductive potential must agree to use an acceptable method of
             birth control during treatment and for 6 months after completion of treatment

        Exclusion Criteria:

          -  Chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry

          -  Patients who are pregnant

          -  Serious co-morbid disease

          -  Uncontrolled bacterial, fungal, or viral infection

          -  Active second malignancy

          -  Individuals who cannot provide informed written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos E. Emmanouilides, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center and Beckman Research Institute, City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <name_title>Christos Emmanouilides, MD / Principal Investigator</name_title>
    <organization>UCLA</organization>
  </responsible_party>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

